TRAX Stock Summary and Trading Ideas (First Tracks Biotherapeutics - | NASDAQ:TRAX)

First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.

What symbol and exchange does First Tracks Biotherapeutics - shares trade?

First Tracks Biotherapeutics - trades on the NASDAQ stock market under the symbol TRAX.

What is First Tracks Biotherapeutics - stock price doing today?

As of May 22, 2026, TRAX stock price climbed to $17.18 with 306,006 million shares trading.

How much is First Tracks Biotherapeutics - worth?

TRAX has a market cap of $599.45 million. This is considered a Small Cap stock.

What are the top ETFs holding First Tracks Biotherapeutics -?

The top ETF exchange traded funds that TRAX belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWO.

What are the support and resistance levels for First Tracks Biotherapeutics - (TRAX)?

TRAX support price is $15.34 and resistance is $18.18 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TRAX shares will trade within this expected range on the day.